CIT-013

CITRYLL COMPLETES PATIENT DOSING IN THE REPEAT DOSE STAGE OF THE PHASE 1 TRIAL FOR THE NOVEL ANTI-INFLAMMATORY CANDIDATE CIT-013 31 July 2024 – Citryll, a clinical-stage biotech company developing first-in-class therapeutics to treat immune-mediated inflammatory diseases, today announces the successful completion of dosing in the repeat dose stage of its Phase 1 trial for its lead drug candidate CIT-013. The Phase 1 first-in-human trial is assessing the safety and tolerability of CIT-013. Part D of the Phase 1 trial is investigating the safety and tolerability of repeat dosing in 9 patient volunteers with rheumatoid arthritis (RA) and 3 healthy volunteers. All trial participants have been enrolled and successfully completed dosing. Results are anticipated in Q4 2024, which, if positive, would lay the groundwork for the initiation of Phase 2a trials. Two Phase 2a studies are planned in patients with RA and hidradenitis suppurativa (HS), Citryll’s lead indications for CIT-013. CIT-013 offers a novel therapeutic approach for treating inflammatory diseases by targeting neutrophil extracellular traps (NETs), which play a significant role in the body’s inflammatory processes. NETs, released during NETosis, can contribute to tissue damage and sustained inflammation when not properly cleared by the body. CIT-013’s dual mode of actions inhibits NET formation and promotes the clearance of existing NETs by specifically targeting citrullinated histones, a hallmark of NETs. Maarten Kraan, M.D., Ph.D., CMO at Citryll, commented: “Reaching this important milestone in the Phase 1 study is testament to hard work across the Citryll team. We look forward to sharing data later this year and plans for Phase 2a trials are underway. We remain excited for the potential of CIT-013, which has demonstrated potent anti-inflammatory effects in preclinical models, positioning it as a potential game-changer in rheumatoid arthritis and hidradenitis suppurativa, as well in a wide range of inflammatory disorders.” Citryll has translated a deep understanding of the neutrophil extracellular trap (NET) pathway to therapeutically address its central role in a broad range of immune-mediated inflammatory diseases. With a unique dual mode of action, the company’s lead antibody, CIT-013, has reached the clinic by demonstrating a precise and powerful ability to control NETs and NETosis. Citryll is initially developing CIT-013 as a novel drug for rheumatoid arthritis and hidradenitis suppurativa, which may serve as enabling indications for a wide spectrum of autoimmune and inflammatory diseases. The initial clinical trials with CIT-013 are expected to provide the foundation for a new treatment paradigm for immune-mediated inflammatory diseases. The content above comes from the network. if any infringement, please contact us to modify.

OSS, the Netherlands--(BUSINESS WIRE)-- Citryll, a clinical-stage biotech company developing first-in-class therapeutics to treat immune-mediated inflammatory diseases, today announced the appointment of Maarten Kraan, M.D., Ph.D., as Chief Medical Officer. Dr. Kraan is a rheumatologist who brings more than 25 years of biopharmaceutical development experience. Dr. Kraan joins Citryll after his CMO role at AM-Pharma. Prior to that, he held various senior medical and R&D positions at Pierre Fabre S.A., AstraZeneca, Roche and Bristol Myers-Squibb. During this time, he was involved in the launch of Nulojix (belatacept) for delayed graft function in renal transplant, as well as the development of Orencia (abatacept), Remicade (infliximab), Humira (adalimumab) and fostamatinib for rheumatoid arthritis. Dr. Kraan will replace Dr. Patrick Round, who will continue to support the company during the transition period. Dr. Kraan’s appointment as CMO comes at an important moment for Citryll, given its recent start of a first-in-human study in rheumatoid arthritis patients with CIT-013, its lead Neutrophil Extracellular Trap-targeting antibody. Importantly, the Company also anticipates the initiation of Phase 2a proof-of-concept trials later this year in rheumatoid arthritis and hidradenitis suppurativa patients. “Citryll’s leadership in therapeutically addressing the Neutrophil Extracellular Trap pathway, a new field of biology, is a unique opportunity to improve current treatment paradigms for rheumatoid arthritis and hidradenitis suppurativa patients,” said Maarten Kraan, M.D., Ph.D., CMO at Citryll. “CIT-013 has great therapeutic potential across autoimmune and autoinflammatory diseases, and I am eager to contribute with my experience to this journey.” “It is a pleasure to welcome Maarten to the team. He brings outstanding industry experience and a demonstrated track record in the clinical development of therapeutics in immune-mediated inflammatory diseases,” said Eduardo Bravo, CEO at Citryll. “Attracting someone of Maarten’s standing to join Citryll is a testimony to the innovation and potential of our therapeutic approach. His arrival comes at the right time as we move towards our proof-of-concept clinical trials.” Editor’s Note Maarten Kraan Bio Maarten Kraan is a rheumatologist and holds an M.D. and Ph.D. in Immunology from Leiden University. Dr. Kraan has more than 25 years of pharmaceutical experience. Most recently, he was CMO at AM-Pharma. At Pierre Fabre S.A., he acted as the head of Research & Development and was responsible for their R&D strategy. Previously, Maarten was head of R&D at Stallergenes Greer Ltd. and CMO at Therachon, which was later acquired by Pfizer. Dr. Kraan also held the positions of Senior Vice President and Head of Innovative Medicines Respiratory and Inflammation at AstraZeneca, as well as the Vice President and Head of Clinical Research and Experimental Development Inflammation at Hoffmann-La Roche. Before this, Dr. Kraan was the Vice President of Immunosciences at Bristol Myers-Squibb and was the Senior Global Director at Schering-Plough, which is now part of MSD (trademark of Merck & Co., Inc., USA). Notably, Dr. Kraan was also involved in the development of Orencia (abatacept), Remicade (infliximab), Humira (adalimumab) and fostamatinib for rheumatoid arthritis. About Citryll Citryll has translated a deep understanding of the neutrophil extracellular trap (NET) pathway to therapeutically address its central role in a broad range of immune-mediated inflammatory diseases. With a unique dual mode of action, the company’s lead antibody, CIT-013, has reached the clinic by demonstrating a precise and powerful ability to control NETs and NETosis. Citryll is initially developing CIT-013 as a novel drug for rheumatoid arthritis and hidradenitis suppurativa, which may serve as enabling indications for a wide spectrum of autoimmune and inflammatory diseases. The initial clinical trials with CIT-013 are expected to provide the foundation for a new treatment paradigm for immune-mediated inflammatory diseases. View source version on businesswire.com: Contacts Citryll Sjoerd van Gorp, COO Email: info@citryll.com Citryll Media Contacts Trophic Communications Gretchen Schweitzer or Priscillia Perrin Email: citryll@trophic.eu Phone: +49 151 21941277 Source: Citryll View this news release online at: